Chronic hepatitis B : an update

By N. Tsai, N. Gitlin. 2010

1,841 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/1e99b4b3e4d13b66c141c2d4da9b33ab33c9bbd9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. NA Terrault
2. Asociacion Latinoamericana para el Estudio del Higado
3. A. Lok
4. J. Kao
5. S. Sarin
6. B. McMahon
7. M. Thompson
8. J. Aberg

Citations in the corpus

• Molecular Biology of Hepatitis B Virus Infection (2015, unknown): “For this and other reasons, antiviral therapy has not been recommended for patients still in the immune tolerant phase of infection (Lok and McMahon, 2009).”
• Update on Prevention, Diagnosis, and Treatment and of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance (2018, background): “Submitted for publication on January 11, 2018 Some persons may test positive for anti-HBc but not HBsAg; they may or may not also have anti-HBs, with the prevalence depending on local endemicity or the risk group (37, 38).”
• Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update (2015, background): “Identification of a HBV-infected person is helpful to [7, 105]: • detect and evaluate stage of the liver disease and extent of liver damage; • plan antiviral therapy which can delay or reverse the progression of liver disease; • permit ultrasound surveillance to detect HCC at a potentially treatable”
• Antiretroviral Treatment of Adult HIV Infection2010 Recommendations of the International AIDS Society–USA Panel (2010, background): “If tenofovir is contraindicated, entecavir should be added.(20) The durability of entecavir is compromised”
• EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. (2015, background): “Patients who have significant liver fibrosis and HBV DNA >2000 IU/ml should be considered for antiviral therapy even if their ALT levels are below two times ULN [251,252].”
• 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis (2016, unknown): “To address hepatitis B, the AASLD practice guidelines were reviewed (85,86).”
• AASLD Guidelines for Treatment of Chronic Hepatitis B (2015, unknown): “Background The objective of HBV treatment is to prevent fibrosis progression and liver-related complications through achievement of sustained suppression of viremia.(2) In those with significant inflammation and/or fibrosis on histology and/or elevated ALT in association with elevated HBV DNA levels”